We love Kim and we thank her for her good work, one of Kim's role at SSH incudes clinical trial risk management , that one has not gone too well, is Kim's work now complete ? was Kim just on loan from Medtronic to get SSH and the FDA up to speed with the interim analysis and trial enrollments up and set FDA guidelines for CP2 ? be very interesting to get some answers , good luck investors.